Squarepoint’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.26M | Buy |
+133,562
| New | +$1.2M | ﹤0.01% | 2721 |
|
|
2025
Q3 | – | Sell |
-79,652
| Closed | -$620K | – | 4786 |
|
|
2025
Q2 | $502K | Buy |
79,652
+22,267
| +39% | +$147K | ﹤0.01% | 3276 |
|
|
2025
Q1 | $368K | Sell |
57,385
-118,606
| -67% | -$980K | ﹤0.01% | 3568 |
|
|
2024
Q4 | $1.41M | Buy |
175,991
+112,812
| +179% | +$1.09M | ﹤0.01% | 2736 |
|
|
2024
Q3 | $798K | Sell |
63,179
-35,598
| -36% | -$460K | ﹤0.01% | 2775 |
|
|
2024
Q2 | $1.25M | Buy |
+98,777
| New | +$994K | ﹤0.01% | 2400 |
|
|
2023
Q4 | – | Sell |
-280,673
| Closed | -$2.03M | – | 4333 |
|
|
2023
Q3 | $2.03M | Buy |
+280,673
| New | +$2.24M | 0.01% | 1814 |
|
|
2023
Q1 | – | Sell |
-213,164
| Closed | -$2.19M | – | 3614 |
|
|
2022
Q4 | $2.19M | Buy |
213,164
+58,654
| +38% | +$1.04M | 0.01% | 1315 |
|
|
2022
Q3 | $2.81M | Sell |
154,510
-71,008
| -31% | -$3.08M | 0.01% | 1091 |
|
|
2022
Q2 | $11.6M | Buy |
225,518
+139,725
| +163% | +$7.24M | 0.06% | 351 |
|
|
2022
Q1 | $6.32M | Buy |
85,793
+40,909
| +91% | +$3.65M | 0.03% | 629 |
|
|
2021
Q4 | $6.42M | Buy |
44,884
+15,715
| +54% | +$2.7M | 0.02% | 694 |
|
|
2021
Q3 | $6.05M | Buy |
29,169
+9,799
| +51% | +$2.16M | 0.02% | 692 |
|
|
2021
Q2 | $4.11M | Buy |
+19,370
| New | +$3.55M | 0.02% | 818 |
|
|
2021
Q1 | – | Sell |
-24,714
| Closed | -$2.76M | – | 3465 |
|
|
2020
Q4 | $2.76M | Sell |
24,714
-31,557
| -56% | -$3.35M | 0.02% | 769 |
|
|
2020
Q3 | $6.1M | Buy |
56,271
+6,361
| +13% | +$775K | 0.08% | 300 |
|
|
2020
Q2 | $4.16M | Buy |
49,910
+4,659
| +10% | +$178K | 0.07% | 391 |
|
|
2020
Q1 | $615K | Buy |
45,251
+2,075
| +5% | +$17.6K | 0.02% | 930 |
|
|
2019
Q4 | $172K | Buy |
+43,176
| New | +$187K | ﹤0.01% | 2254 |
|
|
2019
Q2 | – | Sell |
-35,673
| Closed | -$392K | – | 2581 |
|
|
2019
Q1 | $392K | Buy |
+35,673
| New | +$1.13M | ﹤0.01% | 1617 |
|
|
2017
Q4 | – | Sell |
-4,063
| Closed | -$93K | – | 2268 |
|
|
2017
Q3 | $93K | Buy |
4,063
+2,779
| +216% | +$62.2K | ﹤0.01% | 1519 |
|
|
2017
Q2 | $30K | Sell |
1,284
-3,806
| -75% | -$74.7K | ﹤0.01% | 1479 |
|
|
2017
Q1 | $130K | Sell |
5,090
-7,779
| -60% | -$214K | ﹤0.01% | 1376 |
|
|
2016
Q4 | $324K | Buy |
+12,869
| New | +$375K | 0.01% | 1110 |
|
|
2016
Q2 | – | Sell |
-4,960
| Closed | -$512K | – | 1275 |
|
|
2016
Q1 | $512K | Buy |
4,960
+3,670
| +284% | +$394K | 0.04% | 617 |
|
|
2015
Q4 | $216K | Sell |
1,290
-1,150
| -47% | -$177K | 0.02% | 960 |
|
|
2015
Q3 | $345K | Buy |
+2,440
| New | +$547K | 0.09% | 241 |
|
Other funds holding NVAX
SCM
S
Squarepoint's NVAX Position: Q2 2026 in Review
Squarepoint opened a new position in Novavax (NVAX) in Q2 2026: 133,562 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #2721 among its holdings. This is a return to the name: Squarepoint previously reported a position in NVAX as recently as Q2 2025.
Squarepoint first reported a position in NVAX in Q3 2015 and has held it in 27 quarters since. The position peaked at $11.6M in Q2 2022. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.
- Squarepoint held 133,562 shares of Novavax worth $1.26M as of Q2 2026.
- Novavax was a new Squarepoint position in Q2 2026.
- Novavax made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2721 holding.
- Squarepoint first reported a position in Novavax in Q3 2015 and has held it in 27 quarters since.
- Squarepoint's Novavax position peaked at $11.6M in Q2 2022.
- 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.